Insulet‘s patent describes an insulin delivery system featuring a near field communication (NFC) device that enhances user interaction. The system allows mobile devices to wirelessly receive insulin therapy data, suggest bolus dosages, and prompt user confirmation, streamlining insulin management for users. GlobalData’s report on Insulet gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insulet, Wearable drug delivery devices was a key innovation area identified from patents. Insulet's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Wireless insulin delivery system with nfc communication capabilities
The granted patent US12064591B2 outlines an innovative insulin delivery system that integrates a mobile device with near field communication (NFC) technology to enhance insulin therapy management. The system comprises an insulin delivery device and an NFC device that stores and transmits relevant data. When the mobile device is tapped or brought close to the NFC device, it receives data regarding insulin therapy. The mobile device, equipped with a display and processor, processes this information to suggest a bolus dosage of insulin. Users are prompted to confirm or deny this suggested dosage, ensuring a user-friendly interface for managing their insulin intake.
Further claims detail the functionality of the system, including the ability to transmit confirmed insulin delivery instructions back to the insulin delivery device. The NFC device may also store data related to meal items, enhancing the system's capability to tailor insulin delivery based on dietary intake. Additionally, the mobile device can include an accelerometer to detect movement, which can trigger communication with the NFC device when certain thresholds are met. This feature aims to streamline the interaction between the user and the insulin delivery system, promoting timely and accurate insulin administration. Overall, the patent presents a comprehensive approach to improving diabetes management through technology integration.
To know more about GlobalData’s detailed insights on Insulet, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
